Relmada Therapeutics Inc (NASDAQ:RLMD)’s traded shares stood at 17.55 million during the last session, with the company’s beta value hitting 0.34. At the close of trading, the stock’s price was $0.63, to imply a decrease of -77.26% or -$2.14 in intraday trading. The RLMD share’s 52-week high remains $7.22, putting it -1046.03% down since that peak but still an impressive -198.41% since price per share fell to its 52-week low of $1.88. The company has a valuation of $19.01M, with an average of 0.17 million shares in intraday trading volume over the past 10 days and average of 191.54K shares over the past 3 months.
Analysts have given a consensus recommendation of Sell for Relmada Therapeutics Inc (RLMD), translating to a mean rating of 3.50. Of 1 analyst(s) looking at the stock, 1 analyst(s) give RLMD a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 0 recommend it as a Buy.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
After registering a -77.26% downside in the last session, Relmada Therapeutics Inc (RLMD) has traded red over the past five days. The 5-day price performance for the stock is -76.84%, and -81.58% over 30 days. With these gigs, the year-to-date price performance is -84.78%. Short interest in Relmada Therapeutics Inc (NASDAQ:RLMD) saw shorts transact 1.26 million shares and set a 4.52 days time to cover.
The extremes give us $2 and $2 for target low and target high price respectively. As such, RLMD has been trading -217.46% off suggested target high and -217.46% from its likely low.
Relmada Therapeutics Inc (RLMD) estimates and forecasts
Looking at statistics comparing Relmada Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Relmada Therapeutics Inc (RLMD) shares are -78.72% down over the last 6 months, with its year-to-date growth rate higher than industry average at 21.65% against 16.70%.
RLMD Dividends
Relmada Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
Relmada Therapeutics Inc insiders hold 8.04% of total outstanding shares, with institutional holders owning 46.06% of the shares at 50.09% float percentage. In total, 46.06% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 1.26 million shares (or 4.1706% of shares), all amounting to roughly $3.77 million.
The next major institution holding the largest number of shares is DEEP TRACK CAPITAL, LP with 1.23 million shares, or about 4.0979% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $3.7 million.
